Radiation Oncology Journal

The Korean Society for Radiation Oncology (대한방사선종양학회)
권호 표지

Treatment Outcome and Analysis of the Prognostic Factors of Ductal Carcinoma in situ Treated with Breast Conserving Surgery and Radiotherapy

유방 관상피내암의 유방 보존술 후 방사선 치료의 성적과 예후 인자 분석

  • Kim, Kyoung-Ju (Department of Radiation Oncology, Samsung Medical Center, Sungkyunkwan University School of Medicine) ;
  • Huh, Seung-Jae (Department of Radiation Oncology, Samsung Medical Center, Sungkyunkwan University School of Medicine) ;
  • Park, Won (Department of Radiation Oncology, Samsung Medical Center, Sungkyunkwan University School of Medicine) ;
  • Yang, Jeong-Hyeon (Department of Surgery, Samsung Medical Center, Sungkyunkwan University School of Medicine) ;
  • Nam, Seog-Jin (Department of Surgery, Samsung Medical Center, Sungkyunkwan University School of Medicine) ;
  • Kim, Jeong-Han (Department of Surgery, Samsung Medical Center, Sungkyunkwan University School of Medicine) ;
  • Lee, Sung-Kong (Department of Surgery, Samsung Cheil Hospital, Sungkyunkwan University School of Medicine) ;
  • Lee, Jee-Hyun (Department of Surgery, Samsung Cheil Hospital, Sungkyunkwan University School of Medicine) ;
  • Kang, Sung-Soo (Department of Surgery, Samsung Cheil Hospital, Sungkyunkwan University School of Medicine) ;
  • Lee, Jeong-Eun (Department of Radiation Oncology, Samsung Medical Center, Sungkyunkwan University School of Medicine) ;
  • Kang, Min-Kyu (Department of Radiation Oncology, Samsung Medical Center, Sungkyunkwan University School of Medicine) ;
  • Park, Young-Je (Department of Radiation Oncology, Samsung Medical Center, Sungkyunkwan University School of Medicine) ;
  • Nam, Hee-Rim (Department of Radiation Oncology, Samsung Medical Center, Sungkyunkwan University School of Medicine)
  • 김경주 (성균관대학교 의과대학 삼성서울병원 방사선종양학과) ;
  • 허승재 (성균관대학교 의과대학 삼성서울병원 방사선종양학과) ;
  • 박원 (성균관대학교 의과대학 삼성서울병원 방사선종양학과) ;
  • 양정현 (성균관대학교 의과대학 삼성서울병원 외과) ;
  • 남석진 (성균관대학교 의과대학 삼성서울병원 외과) ;
  • 김정한 (성균관대학교 의과대학 삼성서울병원 외과) ;
  • 이성공 (성균관대학교 의과대학 삼성제일병원 외과) ;
  • 이지현 (성균관대학교 의과대학 삼성제일병원 외과) ;
  • 강성수 (성균관대학교 의과대학 삼성제일병원 외과) ;
  • 이정은 (성균관대학교 의과대학 삼성서울병원 방사선종양학과) ;
  • 강민규 (성균관대학교 의과대학 삼성서울병원 방사선종양학과) ;
  • 박영제 (성균관대학교 의과대학 삼성서울병원 방사선종양학과) ;
  • 남희림 (성균관대학교 의과대학 삼성서울병원 방사선종양학과)
  • Published : 2004.03.01
Download PDF
⟨ Previous Next ⟩

Abstract

Purpose: To evaluate the survival rate, local failure rate and patterns of failure, and analyze the prognostic factors affecting local relapse of ductal carcinoma in situ treated with breast conserving surgery and radiotherapy Materials and Methods: From June 1995 to December 2001, 96 patients with ductal carcinoma in situ treated with breast conserving surgery and radiotherapy were retrospectively analyzed. The operations were either local or wide excision in all patients, with an axillary lymph node dissection performed in some patients. Radiation dose to the whole breast was 50.4 Gy, over 5 weeks, with 1.8 Gy daily fractions, with additional doses ($10\~14$ Gy) administered to the primary tumor bed in some patients with close ($\leq$2 mm) or positive resection margin. The median follow-up period was 43 months (range $10\~102$ months). Results: The 5-year local relapse free survival and overall survival rates were 91 and $100\%$ respectively. Local relapse occurred in 6 patients ($6.3\%$). Of the 6 recurrences, one was invasive ductal cell carcinoma. With the exception of one, all patients recurred 2 years after surgery. There was no regional recurrence or distant metastasis. Five patients with local recurrence were salvaged with total mastectomy, and are alive with no evidence of disease. One patient with recurrent invasive ductal cell carcinoma will receive salvage treatment. On analysis of the prognostic factors affecting local relapse, none of the factors among the age, status of resection margin, comedo type and nuclear grade affected local relapse. Operation extent also did not affect local control (p=0.30). In the patients with close resection margin, boost irradiation to the primary tumor bed did not affect local control (p=1.0). Conclusions: The survival rate and local control of the patients with ductal carcinoma in situ treated with breast conserving surgery and radiotherapy were excellent. Close resection margin and boost irradiation to the primary tumor bed did not affect local relapse, but further follow-up with much more patients is needed.

목적: 유방 관상피내암 환자들의 유방 보존술 및 방사선 치료 후 생존율과 국소 재발률, 재발 양상 및 국소 재발에 영향을 준 인자들을 분석하고, 적절한 치료법을 결정하고자 하였다. 대상 및 방법: 1995년 6월부터 2001년 12월까지 유방 관상피내암으로 유방 보존술 후 방사선 치료를 받았던 96명의 환자를 대상으로 후향적 분석을 시행하였다. 수술은 국소 절제 또는 광범위 절제가 시행되었고, 일부에서 액와 림프절 곽청술이 시행되었다. 방사선 치료는 전 유방에 50.4 Gy /28회를 조사하였고, 절단면에 종양이 있거나 절단면에서 종양이 가까웠던 경우($\leq$ 2 mm) 일부에서 종양이 있었던 부위에 $10\~14$ Gy를 추가 조사하였다. 전체 환자의 중앙 추적 관찰기간은 43개월($12\~102$개월)이었다. 결과: 5년 국소 무병생존율, 생존율은 각각 $91\%,\;100\%$였다. 국소 재발은 6명($6.3\%$)에서 발생하였고, 이 중 침윤성 유방암으로 재발한 환자는 1명이었다. 수술에서 재발까지의 기간은 1명을 제외하고는 모두 2년 이상이었다. 주위 림프절 재발이나 원격전이는 없었다. 재발한 환자 중 5명은 유방 전절제술 후 무병생존 중이고, 1명은 구제 치료예정이다. 국소 재발에 영향을 준 인자들에 대해 분석했을 때, 연령, 절단면 상태, comedo type, 핵분화도 모두 국소 재발에 영향을 주지 않는 것으로 나타났다. 수술 범위에 따라서도 국소 재발에 차이를 보이지 않았고(p=0.30), 절단면이 종양에서 가까웠던 경우 초기 종양 부위에 추가 조사도 국소 재발에 영향을 주지 않았다(p=1.0). 결론: 유방 관상피내암의 치료로 유방 보존술 및 방사선 치료 시행 후 높은 국소 제어율과 생존율을 얻을 수 있었다. 종양이 절단면을 침범하지 않는 한 절단면과 종양과의 거리와 추가 방사선 조사는 국소 재발에 영향을 주지 않는 것으로 나타났으나 향후 더 많은 환자로 장기적인 추적관찰이 필요할 것으로 생각된다.

Keywords

References

  1. Schwartz GF, Solin LJ, Olivotto lA, Ernster VL, Pressman PI. Consensus Conference on the Treatment of In Situ Ductal Carcinoma of the Breast, April 22-25, 1999. Cancer 2000;88:946-954 https://doi.org/10.1002/(SICI)1097-0142(20000215)88:4<946::AID-CNCR26>3.0.CO;2-5
  2. Cancer prevalence statistics. 23th Korean Central Registry Report, National Cancer Center 2002
  3. Ashikari R, Huvos AG, Snyder RE. Prospective study of non-infiltrating carcinoma of the breast. Cancer 1977;39:435-439 https://doi.org/10.1002/1097-0142(197702)39:2<435::AID-CNCR2820390211>3.0.CO;2-W
  4. Sunshine JA, Moseley HS, Fletcher WS, Krippaehne WW. Breast carcinoma in situ. A retrospective review of 112 cases with a minimum 10 year follow-up. Am J Surg 1985;150:44-51 https://doi.org/10.1016/0002-9610(85)90008-X
  5. Rosner D, Bedwani RN, Van a J, Baker HW, Murphy GP. Noninvasive breast carcinoma: results of a national survey by the American College of Surgeons. Ann Surg 1980;192:139-147 https://doi.org/10.1097/00000658-198008000-00001
  6. Silverstein MJ, Barth A, Poller DN, et al. Ten-year results comparing mastectomy to excision and radiation therapy for ductal carcinoma in situ of the breast. Eur J Cancer 1995;31A:1425-1427
  7. Fisher ER, Sass R, Fisher B, Wickerham L, Paik SM. Pathologic findings from the National Surgical Adjuvant Breast Project (protocol 6). I. Intraductal carcinoma (DCIS). Cancer 1986;57:197-208
  8. Fisher B, Dignam J, Wolmark N, et al. Lumpectomy and radiation therapy for the treatment of intraductal breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-17. J Clin Oncol 1998;6:441-452
  9. Julien JP, BUker N, Fentiman IS, et al. Radiotherapy in breast-conserving treatment for ductal carcinoma in situ: first results of the EORTC randomised phase III trial 10853. EORTC Breast Cancer Cooperative Group and EORTC Radiotherapy Group. Lancet 2000;355:528-533 https://doi.org/10.1016/S0140-6736(99)06341-2
  10. Van Zee KJ, Liberman L, Samli B, et al. Long term followup of women with ductal carcinoma in situ treated with breastconserving surgery: the effect of age. Cancer 1999;86:1757-1767 https://doi.org/10.1002/(SICI)1097-0142(19991101)86:9<1757::AID-CNCR18>3.0.CO;2-V
  11. Vicini FA, Kestin LL, Goldstein NS, et al. Impact of young age on outcome in patients with ductal carcinoma-in-situ treated with breast-conserving therapy. J Clin Oncol 2000;18:296-306
  12. Lagios MD, Margolin FR, Westdahl PR, Rose MR. Mammographically detected duct carcinoma in situ. Frequency of local recurrence following tylectomy and prognostic effect of nuclear grade on local recurrence. Cancer 1989;63:618-624 https://doi.org/10.1002/1097-0142(19890215)63:4<618::AID-CNCR2820630403>3.0.CO;2-J
  13. Nakamura S, Woo C, Silberman H, Streeter OE, Lew-insky BS, Silverstein MJ. Breast-conserving therapy for ductal carcinoma in situ: a 20-year experience with excision plus radiation therapy. Am J Surg 2002;184:403-409 https://doi.org/10.1016/S0002-9610(02)01011-5
  14. McCormick B, Rosen PP, Kinne D, Cox L, Yahalom J.Duct carcinoma in situ of the breast: an analysis of local control after conservation surgery and radiotherapy. Int J Radiat Oncol Biol Phys 1991;21:289-292 https://doi.org/10.1016/0360-3016(91)90773-W
  15. Silverstei n MJ, Lag ios M D, G roshen S, et al. The influence of margin width on local control of ductal carcinoma in situ of the breast. N Engl J Med 1999;340:1455-1461 https://doi.org/10.1056/NEJM199905133401902
  16. Weng EY, Juillard GJ, Parker RG, Chang HR, Gornbein JA. Outcomes and factors impacting local recurrence of ductal carcinoma in situ. Cancer 2000;88:1643-1649 https://doi.org/10.1002/(SICI)1097-0142(20000401)88:7<1643::AID-CNCR19>3.0.CO;2-O
  17. Solin LJ, Yeh IT, Kurtz J, et al. Ductal carcinoma in situ (intraductal carcinoma) of the breast treated with breastconserving surgery and definitive irradiation. Correlation of pathologic parameters with outcome of treatment. Cancer 1993;71:2532-2542 https://doi.org/10.1002/1097-0142(19930415)71:8<2532::AID-CNCR2820710817>3.0.CO;2-0
  18. Fisher ER, Costantino J, Fisher B, Palekar AS, Red-mond C, Mamounas E. Pathologic findings from the National Surgical Adjuvant Breast Project (NSABP) Protocol B-17. Intraductal carcinoma (ductal carcinoma in situ). The National Surgical Adjuvant Breast and bowel Project Collaborating Investigators. Cancer 1995;75:1310-1319
  19. Jhingran A, Kim JS, Buchholz T A. Age as a predictor of outcome for women with DCIS treated with breast-conserving surgery and radiation: The University of Texas M.D. Anderson Cancer Center experience. Int J Radiat Oncol Biol Phys 2002;54:804-809
  20. Zafrani B, Fourquet A, Vilcoq JR, Legal M, Calle R. Conservative management of intraductal breast carcinoma with tumorectomy and radiation therapy. Cancer 1986;57:1299-1301 https://doi.org/10.1002/1097-0142(19860401)57:7<1299::AID-CNCR2820570708>3.0.CO;2-B
  21. Rodrigues N, Carter D, Dillon D, Parisot N, Choi DH, Haffty BG. Correlation of clinical and pathologic features withoutcome in patients with ductal carcinoma in situ of the breast treated with breast-conserving surgery and radiotherapy. Int J Radiat Oncol Biol Phys 2002;54:1331-1335 https://doi.org/10.1016/S0360-3016(02)03747-1
  22. Choe JH, Kim SU, Kim JH, Nam SJ, Yang JH. Clinical Features and Pathological Characteristics of Ductal Carcinoma in Situ of the Breast in Mastectomy and Breast Conservative Surgery. J Korean Surg Soc 2003;65:101-108
  23. Price p, Sinnett HD, Gusterson B, Walsh G, A'Hern RP, McKinna JA. Duct carcinoma in situ: predictors of local recurrence and progression in patients treated by surgery alone.Br J Cancer 1990;61:869-872
  24. Silverstein MJ, Lagios MD, Craig PH, et al. A prognostic index for ductal carcinoma in situ of the breast. Cancer 1996;77:2267-2274 https://doi.org/10.1002/(SICI)1097-0142(19960601)77:11<2267::AID-CNCR13>3.0.CO;2-V
  25. Schnitt SJ, Harris JR, Smith BL. Developing a prognostic index for ductal carcinoma in situ of the breast. Are we ther yet? Cancer 1996;77:2189-2192 https://doi.org/10.1002/(SICI)1097-0142(19960601)77:11<2189::AID-CNCR1>3.0.CO;2-L
  26. Taylor ME, Perez CA, Halverson KJ, et al. Factors influencing cosmetic results after conservation therapy for breast cancer. Int J Radiat Oncol Biol Phys 1995;31:753-764 https://doi.org/10.1016/0360-3016(94)00480-3